TALEN

TALEN1-aanat2

ID

ZDB-TALEN-131030-12

Name

TALEN1-aanat2

Previous Names

None

Target

aanat2 (1)

Target Sequence 1

5' - TGGTGGCCTTCATCATT - 3'

Target Sequence 2

5' - TGTTCTAGTTTCTCTT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ct801	aanat2

Expression

Gene expression in Wild Types + TALEN1-aanat2

No data available

Phenotype

Phenotype resulting from TALEN1-aanat2

No data available

Phenotype of all Fish created by or utilizing TALEN1-aanat2

Phenotype	Fish	Conditions	Figures
circadian sleep/wake cycle, sleep increased duration, abnormal	aanat2^ct801/ct801	chemical treatment: mepyramine	Fig. 4 from Gandhi et al., 2015
circadian sleep/wake cycle, sleep decreased duration, abnormal	aanat2^ct801/ct801	control	Fig. 1 , Fig. 4 from Gandhi et al., 2015
sleep decreased duration, abnormal	aanat2^ct801/ct801	constant dark	Fig. 2 from Gandhi et al., 2015
sleep decreased occurrence, abnormal	aanat2^ct801/ct801	standard conditions	Fig. S3 from Oikonomou et al., 2019
circadian sleep/wake cycle disrupted, abnormal	aanat2^ct801/ct801	constant dark	Fig. 2 from Gandhi et al., 2015
locomotion involved in locomotory behavior increased occurrence, abnormal	aanat2^ct801/ct801	standard conditions	Fig. 1 from Gandhi et al., 2015
sleep decreased duration, abnormal	aanat2^ct801/ct801	standard conditions	Fig. 1 from Gandhi et al., 2015
circadian sleep/wake cycle disrupted, abnormal	aanat2^ct801/ct801	constant dark, chemical treatment: melatonin	Fig. 2 from Gandhi et al., 2015
locomotion involved in locomotory behavior increased occurrence, abnormal	aanat2^ct801/ct801	constant dark	Fig. 2 from Gandhi et al., 2015
locomotion involved in locomotory behavior decreased occurrence, abnormal	aanat2^ct801/ct801	chemical treatment: mepyramine	Fig. 4 from Gandhi et al., 2015
circadian sleep/wake cycle, sleep increased duration, abnormal	aanat2^ct801/+	chemical treatment: mepyramine	Fig. 4 from Gandhi et al., 2015
locomotion involved in locomotory behavior decreased occurrence, abnormal	aanat2^ct801/+	chemical treatment: N-ethyl-5'-carboxamidoadenosine	Fig. 4 from Gandhi et al., 2015
locomotion involved in locomotory behavior decreased occurrence, abnormal	aanat2^ct801/+	chemical treatment: mepyramine	Fig. 4 from Gandhi et al., 2015
neuron chromosome organization decreased occurrence, abnormal	aanat2^ct801/ct801; biu13Tg; nns6Tg	control	Fig. 2 from Zada et al., 2019
sleep decreased occurrence, exacerbated	aanat2^ct801/ct801; tph2^ct817/ct817	standard conditions	Fig. S3 from Oikonomou et al., 2019

Citations